Irritable bowel syndrome affects roughly one in ten adults globally, yet its management remains inconsistent and often frustrating for both patients and clinicians. A clinical overview published in Australian Prescriber consolidates current diagnostic and therapeutic standards under the updated Rome V framework — a development that carries practical weight for the estimated millions of Australians navigating this condition without a clear biological marker to anchor their diagnosis.
IBS is now formally classified as a disorder of gut-brain interaction rather than a purely functional or psychosomatic condition — a distinction that reframes how symptoms are interpreted and treated. Diagnosis rests on meeting Rome V symptom criteria (recurrent abdominal pain linked to defecation or stool changes) in the absence of alarm features such as rectal bleeding, unexplained weight loss, or a family history of colorectal cancer. A streamlined screening panel — full blood count, C-reactive protein, and coeliac serology — is sufficient when red flags are absent. Pharmacological management is subtype-driven: antispasmodics and neuromodulators including tricyclic antidepressants for pain-predominant presentations, osmotic laxatives for constipation-predominant IBS, and antidiarrhoeals for diarrhea-predominant subtypes. Notably, the review withholds endorsement of probiotics, faecal microbiota transplantation, and mesalamine, citing insufficient evidence.
The gut-brain interaction framing is significant because it legitimizes psychological therapies — cognitive behavioral therapy and gut-directed hypnotherapy chief among them — as first-line components rather than adjuncts of last resort. This aligns with a growing body of evidence showing that central sensitization and altered visceral pain processing are mechanistically central to IBS, not merely comorbid. The explicit caution around probiotics and FMT is a useful corrective against considerable commercial enthusiasm in this space; current trial data remain heterogeneous and largely underpowered. Clinicians and patients alike should note that IBS subtypes are not static — patients may shift categories over time — which demands periodic reassessment of treatment strategy rather than set-and-forget prescribing.
